Esophageal Cancer Pipeline H1 2016 Market Report on 54 Companies

India - English

News provided by

May 04, 2016, 10:00 ET

PUNE, India, May 5, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Esophageal Cancer - Pipeline Review, H1 2016" market research report that offers comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Esophageal Cancer with 83 market data tables and 16 figures, spread across 448 pages is available at http://www.rnrmarketresearch.com/esophageal-cancer-pipeline-review-h1-2016-market-report.html .

The report also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Esophageal Cancer Pipeline Review, H1 2016 report include Adaptimmune Therapeutics Plc, Advantagene, Inc., Advaxis, Inc., Advenchen Laboratories, LLC, Almac Discovery Limited, Amgen Inc., ArQule, Inc., Array BioPharma Inc., Aslan Pharmaceuticals Pte. Ltd., ATLAB Pharma SAS, Bayer AG, Betta Pharmaceuticals Co. Ltd., Boehringer Ingelheim GmbH, Celgene Corporation, Celldex Therapeutics, Inc., Cellectar Biosciences, Inc., Cerulean Pharma, Inc., Cyclacel Pharmaceuticals, Inc., Genmab A/S, Glycotope GmbH, Hutchison MediPharma Limited, Ignyta, Inc., ImmunoFrontier, Inc., ImmunoGen, Inc., Immunomedics, Inc., Johnson & Johnson, Karyopharm Therapeutics, Inc., Komipharm International Co., Ltd., MacroGenics, Inc., Mebiopharm Co., Ltd., MedImmune, LLC, Merck & Co., Inc., Novartis AG, Omeros Corporation, Omnitura Therapeutics Inc., Oncolys BioPharma Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Proteo, Inc., Puma Biotechnology, Inc., Shenzen SiBiono GeneTech Co., Ltd., Shionogi & Co., Ltd., Sihuan Pharmaceutical Holdings Group Ltd., Spectrum Pharmaceuticals, Inc., Symphogen A/S, Synta Pharmaceuticals Corp., Taiho Pharmaceutical Co., Ltd., Taiwan Liposome Company, Ltd., Takara Bio Inc., tella Inc, TG Therapeutics, Inc., Transgene Biotek Limited, VioQuest Pharmaceuticals, Inc. and Virocan Therapeutics Private Limited.

Drug profiles discussed in this research report includes (tipiracil hydrochloride + trifluridine), 1-BB1, ADXS-HER2, afatinib dimaleate, AL-3818, ALM-301, alpelisib, AMG-337, apatinib, ATL-101, binimetinib, CDX-1401, Cellular Immunotherapy for Oncology, Cellular Immunotherapy for Oncology, Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology, Cellular Immunotherapy to Target NY-ESO-1 for Oncology, cetuximab biobetter, CGX-1321, CRLX-101, CYC-140, Cytokine Induced Killer Cells + Dendritic Cells, dacomitinib, DKN-01, donafenib, durvalumab, elgemtumab, erdafitinib, futuximab, ganetespib, gedatolisib, Gene Therapy for Esophageal Cancer, Gene Therapy to Activate p53 for Oncology, GSK-3377794, HMPL-309, I131-CLR1404, icotinib hydrochloride, IMF-001, IMGN-289, KML-001, margetuximab, MBP-426, MMD-37K, Monoclonal Antibodies to Inhibit PD-L2 for Esophageal cancer, MVXONCO-1, neratinib, nimotuzumab, nintedanib, nivolumab, OBP-301, OMN-54, paclitaxel albumin bound, panitumumab, pasireotide ER, PCA-062, pembrolizumab, pralatrexate, rAAVVICN-003, RXDX-106, S-222611, S-588410, sacituzumab, selinexor, sirotinib, Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes, Small Molecule to Target LGR5 for Esophageal Adenocarcinoma, Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer, SMYD-2BAY02, TBI-1201, TBL-0805E, TGR-1202, tiprelestat, tisotumab vedotin, tivantinib, TLC-388, triciribine phosphate, Vaccine for Esophageal Cancer and Colorectal Cancer and varlitinib.

Order a copy of Esophageal Cancer - Pipeline Review, H1 2016 market research report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=539820 .

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer and reviews pipeline therapeutics for Esophageal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Esophageal Cancer therapeutics and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Esophageal Cancer.

Another newly published market research report titled on Metastatic Pancreatic Cancer - Pipeline Review, H1 2016 reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Metastatic Pancreatic Cancer Pipeline market research report of 456 pages is available at http://www.rnrmarketresearch.com/metastatic-pancreatic-cancer-pipeline-review-h1-2016-market-report.html .

Explore more reports on Cancer Therapeutics.

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
[email protected]

Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research